health canada approval zepbound tirzepatide obesity canada 2024 2025 A 72-week trial compared the two leading GLP-1 medications in adults with (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the Health Canada Approves Zepbound for

Keto was originally devised as a treatment for other health conditions, but as it turns out, it can also help curb cravings and, in some cases, create substantial weight loss

Mounjaro is suitable for adults with: A BMI of 30 or over (obesity) A BMI of 27 or over (overweight) and at least one weight-related health issue like prediabetes, high blood pressure, high cholesterol, or heart problems

The prescription must include a clinical justification for compounded tirzepatide over the commercially available product

They will consider your unique health needs, lifestyle, and preferences, and guide you in making an informed decision about the most suitable weight management solution